NASDAQ (US) Website – NASDAQ Investor Overview
All Documents


Events & Presentations

Press Releases

Aug 09, 2022
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer    read more...
Aug 04, 2022
BeiGene Reports Second Quarter 2022 Financial Results   
Jul 14, 2022
BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC    read more...
Press Releases

Thank you for your interest in Beigene, Ltd ! You will receive an email shortly. Please confirm your email address by clicking the link inside.

Back to the form